These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2453474)

  • 1. Use of antisera to the isolated alpha and beta subunits of C3 as probes to study functional sites present on particle-bound C3b but absent on native soluble forms of C3.
    Whaley K; Nilsson U
    Int Arch Allergy Appl Immunol; 1988; 86(1):55-61. PubMed ID: 2453474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules.
    Medicus RG; Melamed J; Arnaout MA
    Eur J Immunol; 1983 Jun; 13(6):465-70. PubMed ID: 6222909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analogous antigenic alterations elicited in C3 by physiologic binding and by denaturation in the presence of sodium dodecylsulfate.
    Nilsson UR; Nilsson B
    J Immunol; 1982 Dec; 129(6):2594-7. PubMed ID: 6183339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xenoantiserum to human C3 receptors: its preparation and effect on the C3b and C3d receptors of tonsil cells and the C3b receptors of erythrocytes and neutrophils.
    Gerdes J; Klatt U; Stein H
    Immunology; 1980 Jan; 39(1):75-84. PubMed ID: 6991397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. Enhancement of antibody-mediated cellular cytotoxicity.
    Perlmann H; Perlmann P; Schreiber RD; Müller-Eberhard HJ
    J Exp Med; 1981 Jun; 153(6):1592-603. PubMed ID: 7252421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localisation of a group of antigenic sites in complement component C3, and identification of a new fragmentation pattern.
    Fontaine M; Sim RB
    Biochim Biophys Acta; 1984 Sep; 789(2):119-27. PubMed ID: 6206896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes.
    Medof ME; Iida K; Mold C; Nussenzweig V
    J Exp Med; 1982 Dec; 156(6):1739-54. PubMed ID: 7175439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SDS denaturation of complement factor C3 as a model for allosteric modifications occurring during C3b binding: demonstration of a profound conformational change by means of circular dichroism and quantitative immunoprecipitation.
    Nilsson B; Nilsson UR
    Immunol Lett; 1986 Aug; 13(1-2):11-4. PubMed ID: 2428739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Qualitative and quantitative assessment of C3-receptor reactivities on lymphoid and phagocytic cells.
    Schmitt M; Mussel HH; Dierich MP
    J Immunol; 1981 May; 126(5):2042-7. PubMed ID: 7217681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
    Newman SL; Mikus LK
    J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Native C3 does not bind to the C3b receptor (CR1) of human blood B lymphocytes or alter immunoglobulin synthesis.
    Berger M; Fleisher TA
    J Immunol; 1983 Mar; 130(3):1021-3. PubMed ID: 6600466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C3 cleaved by membrane proteases binds to C3b acceptors expressed on concanavalin A-stimulated human lymphocytes and enhances antibody-dependent cellular cytotoxicity.
    Erdei A; Benczur M; Fábry Z; Dierich MP; Gergely J
    Scand J Immunol; 1984 Aug; 20(2):125-31. PubMed ID: 6236547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of C3 and C3b with immunoglobulin G.
    Kulics J; Rajnavölgyi E; Füst G; Gergely J
    Mol Immunol; 1983 Aug; 20(8):805-10. PubMed ID: 6621540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The C(H)1 domain of IgG is not essential for C3 covalent binding: importance of the other constant domains as targets for C3.
    Muñoz E; Vidarte L; Casado MT; Pastor C; Vivanco F
    Int Immunol; 1998 Feb; 10(2):97-106. PubMed ID: 9580208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of gp 140, a C3b-binding membrane component present on Raji cells: a comparison with factor H.
    Frade R; Barel M; Krikorian L; Charriaut C
    Eur J Immunol; 1984 Jun; 14(6):542-8. PubMed ID: 6234177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Covalent association of C3b with C4b within C5 convertase of the classical complement pathway.
    Takata Y; Kinoshita T; Kozono H; Takeda J; Tanaka E; Hong K; Inoue K
    J Exp Med; 1987 Jun; 165(6):1494-507. PubMed ID: 3495629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
    Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
    Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates.
    Antón LC; Ruiz S; Barrio E; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1994 Mar; 24(3):599-604. PubMed ID: 8125130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probing functional sites on complement protein B with monoclonal antibodies. Evidence for C3b-binding sites on Ba.
    Ueda A; Kearney JF; Roux KH; Volanakis JE
    J Immunol; 1987 Feb; 138(4):1143-9. PubMed ID: 2433342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.